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ABSTRACT We have studied the effects of the local anesthetic lidocaine, and the general anesthetic halothane, on the function
and oligomeric state of the Ca-ATPase in cardiac sarcoplasmic reticulum (SR). Oligomeric changes were detected by time-
resolved phosphorescence anisotropy (TPA). Lidocaine inhibited and aggregated the Ca-ATPase in cardiac SA. Micromolar
calcium or 0.5 M lithium chloride protected against lidocaine-induced inhibition, indicating that electrostatic interactions are
essential to lidocaine inhibition of the Ca-ATPase. The phospholamban (PLB) antibody 2D12, which mimics PLB phospho-
rylation, had no effect on lidocaine inhibition of the Ca-ATPase in cardiac SA. Inhibition and aggregation of the Ca-ATPase in
cardiac SR occurred at lower concentrations of lidocaine than necessary to inhibit and aggregate the Ca-ATPase in skeletal
SR, suggesting that the cardiac isoform of the enzyme has a higher affinity for lidocaine. Halothane inhibited and aggregated
the Ca-ATPase in cardiac SA. Both inhibition and aggregation of the Ca-ATPase by halothane were much greater in the presence
of PLB antibody or when PLB was phosphorylated, indicating a protective effect of PLB on halothane-induced inhibition and
aggregation. The effects of halothane on cardiac SR are opposite from the effects of halothane observed in skeletal SR, where
halothane activates and dissociates the Ca-ATPase. These results underscore the crucial role of protein-protein interactions
on Ca-ATPase regulation and anesthetic perturbation of cardiac SA.
INTRODUCTION
The Ca-ATPase of SR pumps Ca from the sarcoplasm into
the SR lumen to allow relaxation of both skeletal and cardiac
muscle. Previous investigations into the regulatory mecha-
nisms of the SR Ca-ATPase in skeletal muscle have estab-
lished the importance of the Ca-ATPase oligomeric state to
enzymatic function (Squier et aI., 1988b; Voss et aI., 1991;
Karon and Thomas, 1993). Agents that aggregate the
Ca-ATPase in skeletal SR, such as chemical cross-linkers,
the amphipathic peptide melittin, or the local anesthetic li-
docaine, inhibit enzymatic activity (Squier et aI., 1988b;
Mahaney and Thomas, 1991; Voss et aI., 1991; Kutchai et aI.,
1994). Agents that dissociate the Ca-ATPase, such as the
volatile anesthetics ether and halothane, activate the enzyme
(Bigelow and Thomas, 1987: Birmachu et aI., 1989; Karon
and Thomas, 1993).
In cardiac SR, the integral membrane protein PLB regu-
lates the enzymatic activity of the Ca-ATPase (Lindemann
et aI., 1983). At submicromolar levels of Ca, PLB-ATPase
interaction results in an inhibition of enzymatic activity
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(James et aI., 1989; Sham et aI., 1991). PLB-ATPase inter-
action (at submicromolar Ca) also results in decreased
Ca-ATPase rotational mobility (compared with high Ca or
PLB phosphorylation) (Voss et aI., 1994). Upon PLB phos-
phorylation or addition of micromolar Ca, the resting inhi-
bition of the Ca-ATPase is relieved (the enzyme is activated).
This activation correlates with an increase in the rotational
mobility of the Ca-ATPase, most likely because the physical
interaction between PLB and the Ca-ATPase is disrupted,
allowing large Ca-ATPase oligomers to dissociate (Voss
et aI., 1994). The physical and biochemical mechanisms by
which PLB regulates Ca-ATPase function are just beginning
to be elucidated.
Local anesthetics, such as lidocaine, have been reported to
inhibit the Ca-ATPase in cardiac SR (Katz et aI., 1975). Li-
docaine also acts as an anti-arrhythmic agent in the heart,
although the concentrations of lidocaine necessary to inhibit
the Ca-ATPase are far greater than effective anti-arrhythmic
levels (Katz et aI., 1975). In skeletal muscle, cationic agents
similar to lidocaine have been found to inhibit the
Ca-ATPase in a manner analogous to the action of PLB in
cardiac SR (Mahaney and Thomas, 1991; Hughes et aI.,
1994). In addition, lidocaine induces the formation of larger
Ca-ATPase oligomers in skeletal SR (Kutchai et aI., 1994),
similar to the effects of unphosphorylated PLB in cardiac SR.
Therefore, studying lidocaine's effect in cardiac SR may not
only provide more information on the effects of anti-
arrhythmic agents on the heart but also provide information
about the regulation of the Ca-ATPase by PLB.
Volatile anesthetics, such as halothane, are known to de-
press myocardial contractility at clinical levels, and this ef-
fect may be due to a defect in SR Ca regulation (Rusy and
Komai, 1987). Thus, an understanding of halothane action on
the Ca-ATPase in cardiac SR is crucial to understanding the
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Data analysis
Phosphorescence experiments
TPA decays were analyzed by fitting them as described by Mersol et al.
(1995), with the nonlinear least squares algorithm of Marquardt (Bevington,
1969). The quality of the fit was gauged by comparing XZ values and by
evaluating the residuals. Previous reports from this laboratory (Birmachu
and Thomas, 1990; Karon et aI., 1994; Mersol et aI., 1995) have shown that
the TPA of ERITC-SR is dominated by the uniaxial rotational diffusion of
the labeled Ca-ATPase about an axis normal to the bilayer, and that it is a
good approximation to fit a sum of three exponentially decaying terms plus
a constant term to the data
where <Pi' the rotational correlation time of the ith component, is inversely
proportional to the rotational diffusion coefficient Di" Ai is proportional to
the mole fraction of Ca-ATPase with a correlation time <Pi' and Aoo is the
normalized residual anisotropy (roo/ro)' The value of Aoo depends on the
orientation of the probe transition dipoles with respect to the membrane
normal (see Scheme 1) as well as the fraction of Ca-ATPase molecules
immobile on the time scale of the experiment (Cornea and Thomas, 1994;
Karon et aI., 1994; Mersol et aI., 1994). The orientational dependence ofAoo
is described by
(1)
(2)
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where I vv and I Vh are the vertical and horizontal components of the emission
after excitation with a vertically polarized pulse. Time-resolved phospho-
rescence anisotropy (TPA) decays were recorded with an instrument de-
scribed previously (Ludescher and Thomas, 1988), by signal averaging the
time-dependent phosphorescence decays with a single detector and a po-
larizer that alternates between vertical (/vv(t» and horizontal (/vh(t» ori-
entation every 2000 laser flashes. G is an instrumental correction factor,
determined by measuring the anisotropy of a s~lution of free dye under
experimental conditions and adjusting G to give an anisotropy value ofzero,
the theoretical value for a freely tumbling chromophore (G generally varies
between 0.996-1.004 for our spectrometer).
The Ca-ATPase was specifically labeled at lysine 515 with ERITC as de-
scribed previously (Birmachu and Thomas, 1990). After labeling, samples
were diluted to a concentration of 0.24l.3 mg/ml in the standard buffer.
Oxygen was removed from the sample by the addition of 200 lLg/ml glucose
oxidase, 30 lLg/ml catalase, and 5 mg/ml f3-o-glucose (Eads et aI., 1984).
Deoxygenation was allowed to proceed for 20 min before data collection.
Lidocaine and halothane were added in a manner analogous to that used for
ATPase activity experiments and allowed to incubate 5-10 min before data
collection. Neither halothane, lidocaine, nor oxygen that may have entered
the sample upon addition of anesthetics was found to measurably change the
probe luminescence lifetime.
The anisotropy is defined as
Jones (Cantilina et aI., 1993), and activity experiments in the presence of
PLB Ab were performed by incubating Ab (1:2 Ab:Ca-ATPase by weight)
at 25°C for 20 min before the start of the assay. Ca uptake measurements
were obtained as described previously (Kutchai and Campbell, 1989) in the
presence of 50 mM MOPS, 70 mM KCl, 0.5 mM EGTA, 5 mM potassium
oxalate, 5 mM sodium azide, 0.383 mM CaCl2 (free [Cal = lILM), llLCi
45Ca/ml, and 3 mM MgATP, with and without llLM ruthenium red and 0-30
mM lidocaine. For Ca-ATPase activity and TPA experiments, PLB was
specifically phosphorylated in CSR as described previously (Voss et aI.,
1994).
ERITC was obtained from Molecular Probes (Eugene, OR) and stored in
DMF under liquid nitrogen. Halothane (99%) was obtained from Aldrich
(Milwaukee, WI). Lidocaine, catalase, glucose oxidase, f3-o-glucose, pyru-
vate kinase, lactate dehydrogenase, phosphoenol pyruvate, ATP, and NADH
were purchased from Sigma Chemical Co. (St. Louis, MO). The calcium
ionophore A23187 was obtained from Calbiochem (San Diego, CA).
ATPase assays and spectroscopic measurements were carried out at 25°C
in a standard buffer containing 50 mM MOPS (pH 7), 60 mM KCl, 2 mM
MgCI2, and either CaCl2 alone or 5 mM EGTA + CaCl2 to reach the desired
concentration of free Ca. Unless otherwise indicated, [Cal will be used to
indicate the concentration of free ionized Ca2+, calculated as described
previously (Voss et aI., 1994).
Preparations and assays
MATERIALS AND METHODS
Reagents and solutions
action of anesthetics on the heart. Previous studies of the
effects of anesthetics in cardiac SR have reached different
conclusions, finding either activation or inhibition of the
Ca-ATPase by halothane (Lain et aI., 1968; Casella et aI.,
1987; Frazer and Lynch, 1992). It was previously observed
that halothane dissociates Ca-ATPase oligomers in skeletal
SR, correlating with activation of the Ca-ATPase (Karon and
Thomas, 1993; Karon et aI., 1994).
Because it has been established in skeletal SR that
anesthetic-induced activation (inhibition) correlates well
with anesthetic-induced dissociation (aggregation) of the
Ca-ATPase (Thomas and Karon, 1994), it is important to
study not only functional but also physical effects of anes-
thetics in cardiac SR. However, none of the studies on li-
docaine or halothane action in cardiac SR has considered the
effects of these anesthetic agents on the oligomeric state of
the Ca-ATPase. Moreover, because PLB regulation of the
Ca-ATPase also involves changes in oligomeric state (Voss
et aI., 1994), the role of PLB in mediating anesthetic effects
on Ca-ATPase function and oligomeric state must be con-
sidered. In the present study, to gain a more complete un-
derstanding of anesthetic action in the heart, we have studied
the effects of halothane and lidocaine (as mediated by PLB)
on Ca-ATPase oligomeric state, as detected by time-resolved
phosphorescence anisotropy (TPA), and enzymatic function
in cardiac SR.
CSR vesicles prepared from canine ventricular tissue were kindly provided
by Dr. Joseph J. Feher (Feher and Briggs, 1983). Ca-ATPase activity was
assayed by an enzyme-linked, continuous assay (Karon et aI., 1994). Be-
tween 5 and 50 lLg/ml of Ca-ATPase in SR vesicles was added to a buffer
containing 2 mM phosphoenol pyruvate, 0.24 mM NADH, 120 IV of pyru-
vate kinase, and 120 IU of lactate dehydrogenase. The assay mixture also
contained llLg/ml of the ionophore A23187 (in DMF) to prevent a buildup
of calcium inside the vesicles that might inhibit the Ca-ATPase activity.
Lidocaine (in 50% ethanol) and halothane (in DMF) were added to the
samples and allowed to incubate for 5 min before data collection. The vol-
ume of ethanol or DMF added «1% v/v) to the sample did not affect
Ca-ATPase activity. Halothane was added as described previously (Karon
and Thomas, 1993), such that partitioning of halothane into the vapor phase
was negligible. MgATP (1 mM) was added to start the assay, and the ab-
sorbance ofNADH was followed at 340 nm to determine the amount ofATP
hydrolyzed. The monoclonal anti-PLB Ab 2D12 was provided by Dr. Larry
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where P2(X) = (3r - 1)/2, 6. is the angle between the probe absorption
dipole and the membrane normal, fie is the angle between the probe emission
dipole and the membrane normal, and S is the angle between the absorption
and emission transition dipoles (Lipari & Szabo, 1980). An increase in Aoo
due to an increased fraction of immobile aggregates can be expressed as A':'
(Karon and Thomas, 1993)
SCHEME 1. An illustration of the angles used in Eqs. 3 and 8. The probe's
absorption (il.) and emission (ilJ dipoles are shown relative to the membrane
normal. 6. is the angle between the membrane normal and the probe's ab-
sorption dipole, and fie is the angle between the membrane normal and the
probe's emission dipole. S is the angle between the probe's absorption and
emission dipoles, and C/>.. is the azimuthal angle between the probe's ab-
sorption and emission dipoles.
(9)
(10)
is given in general form by
The more complete model (described by Eqs. 5 and 7-10) differs from
previous analysis (described by Eqs. 2-4 and 6) only in 1), the inclusion of
the bi-exponential decay for each species (Eq. 7); 2), the explicit inclusion
of the fast wobble parameter K (Eqs. 7, 9, and 10); and 3), the explicit
inclusion of the angular dependence of the amplitudes of the exponentially
decaying terms (Eq. 8, a-c). It has been observed previously that TPA decays
of ERITC-SR are best fit by a function that includes three rotating species.
Each species is assumed to have the same values of c/>ea' 6" and fie and to
differ from the other species only in its diffusion coefficient, presumably due
to differences in aggregation state (Mersol et aI., 1994).
The rotational diffusion coefficient of these rotating species is predicted
by the Saffman-Delbriick equation (Saffman and Delbriick, 1975)
where A6 describes the amplitude of the motion. This motion may result
from the site of probe attachment (Lys 515) undergoing segmental motion
or from partial freedom of motion of the probe itself around the site of
attachment. It can be modeled as wobble-in-a-cone type motion, in which
the probe is free to move within a cone of half-angle fie centered about an
axis determined by the probe's local environment. In this case K is given
by (Kinosita et aI., 1977)
RRR
~~~
Here, Di is the rotational diffusion coefficient about the normal to the mem-
brane, and c/>,e is the azimuthal angle between the absorption and emission
transition dipoles of the probe (see Scheme 1). K is the order parameter for
fast (sub-microsecond) rotation of the probe with respect to the protein and
(11)
RESULTS
Effects of lidocaine on Ca-ATPase activity and
uptake in cardiac SR
To determine the effect of lidocaine on the function of the
Ca-ATPase in cardiac SR, we measured the rate of Ca-
dependent ATP hydrolysis (Ca-ATPase activity) in the pres-
ence of 1 JLg/rnl ionophore A23187 and the rate of Ca uptake
by SR vesicles in the absence and presence of 1 JLM of the
Ca release inhibitor ruthenium red. Ca-ATPase activity and
uptake rates measured at 1 JLM [Cal are shown in Fig. 1.
Lidocaine inhibited Ca-ATPase activity at IJLM [Ca], and the
inhibition of Ca-ATPase activity by lidocaine paralleled the
inhibition of Ca uptake by lidocaine in the absence of ru-
thenium red. In the presence of 1 JLM ruthenium red, Ca
uptake rates were higher and inhibition of lidocaine steeper
than observed in the absence of the Ca release inhibitor. It
has previously been determined that ruthenium red (up to 20
JLM) does not affect the rate of Ca uptake by the Ca-ATPase
and thus most likely increases the coupling ratio (ratio of Ca
where ° is the effective radius of the protein in the bilayer, h is the height
of the protein in contact with the membrane, k is Boltzmann's constant, 1)
is the effective membrane viscosity, and T is the absolute temperature. Thus,
the rotational diffusion coefficient is proportional to the lipid fluidity (T/1)
Squier et aI., 1988b) and inversely proportional to the intramembrane cross-
sectional area ('lT02) of the protein. An increase in lipid fluidity or a decrease
in the effective radius of the rotating species will cause an increase in the
protein's rotational diffusion coefficient. This has been confirmed by pre-
vious studies on the Ca-ATPase using saturation transfer electron para-
magnetic resonance (Squier et al., 1988a) and phosphorescence anisotropy
(Birrnachu and Thomas, 1990). The latter study showed that correlation
times (c/>j, eq 2) obtained by fitting TPA decays can be used to determine
the sizes of Ca-ATPase oligomers, and normalized amplitudes (Ai in Eq. 2
andf. in Eq. 5) can be used to determine the mole fractions of oligomers
present in SR.
(6)
(7)
(4)
(5)
(8a)
(Be)
(8b)
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with
where Aooo = 0.18, determined experimentally by measuring the residual
anisotropy of the Ca-ATPase in the absence of large aggregates (light skel-
etal SR at 25°C) (Karon et al., 1994).
In the present study we have also fit the data to the analytical function
that Eq. 2 approximates, which incorporates all of the terms that describe
the anisotropy of uniaxially rotating chromophores
where f. is the mole fraction associated with the ith rotating species, andI.
is the mole fraction of Ca-ATPase not rotating on the time scale of the
experiment (immobilized Ca-ATPase). With this expression, changes in the
mole fraction of immobile Ca-ATPase induced by SR perturbants can be
directly determined, independent of the orientation of the probe (Mersol
et aI., 1994). Because the probe dipole angles are most likely identical for
ERITC-labeled skeletal and cardiac SR (Voss et aI., 1994), the value ofAooo
(Eq. 3) determined from TPA decays of ERITC-skeletal SR was used to
calculate the value of A':' (Eq. 4) for ERITC-CSR samples. A.:, is related to
the mole fraction of immobilized Ca-ATPase by the following expression
(Cornea and Thomas, 1994)
Thus, the value ofI. determined directly by fitting TPA decays to the uniaxial
model (Eq. 5) can be compared with the value ofI. calculated by fitting TPA
decays to the simple multiexponential model (Eqs. 2-4 and 6).
The expression for the individual anisotropy of the ith uniaxially rotating
species is given by (Szabo, 1984)
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FIGURE 1 Ca-ATPase activity at 25°C and Ip.M [Cal in the presence
of 1 p.glml of the ionophore A23187 (.); compared with Ca uptake in
the absence (e) and presence ( • ) of 1 p.M ruthenium red at 25°C, as
described in Materials and Methods. IV, p.mol of ATP hydrolyzed (Ca
uptake)/mg SR protein/min. The coupling ratio (ratio of Ca uptake to
ATPase activity) is approximately 1 in the presence of ruthenium red,
but much less in the absence of ruthenium. Each point represents the
average of 2-4 experiments :!: SD.
uptake to ATPase activity) by inhibiting Ca release from SR
(Moutin et aI., 1992). The higher rate of uptake observed
suggests that Ca uptake was more tightly coupled to ATP
hydrolysis in the presence of ruthenium red but that lidocaine
may have had two effects in the presence of ruthenium:
(1) inhibition of the Ca-ATPase and (2) uncoupling Ca trans-
port from ATP hydrolysis.
Because it has previously been observed that lidocaine
inhibition is partially reversed by Ca (Katz et aI., 1975), we
determined the effects of lidocaine on the activation of the
Ca-ATPase by Ca. In cardiac SR the Km for Ca has been
reported to be O.2-1.S JLM [Ca) (Sasaki et aI., 1992; Cantilina
et aI., 1993). As shown in Fig. 2, lidocaine had no significant
effect on the activation of the Ca-ATPase by Ca in the range
of o-S JLM. We conclude that lidocaine had no effect on the
Km for Ca.
5 10 15 20
LIDOCAINE (mM)
25 30
However, higher Ca levels did have a protective effect
against lidocaine inhibition of the Ca-ATPase in cardiac SR.
Inhibition of the Ca-ATPase was greatest at ISO nM [Cal,
with Ca levels up to SOO JLM having a protective effect
against lidocaine inhibition (Fig. 3). To determine whether
Ca (as a specific substrate) was necessary to protect the
Ca-ATPase against lidocaine-induced inhibition, we deter-
mined the effect of0.5 M LiCI in the presence of 20 JLM [Ca)
on the inhibition of the Ca-ATPase by lidocaine (Fig. 3). This
concentration of LiCI was previously shown to protect
against Ca-ATPase inhibition by polylysine in skeletal SR,
presumably by acting as a nonspecific cation interfering with
electrostatic interactions between polylysine and the
Ca-ATPase (Vosset aI., 1991). In the presence ofO.S M LiCl,
lidocaine between 0 and 30 mM had no effect on Ca-ATPase
activity (Fig. 3).
To further define the role of cationic charge in lidocaine-
induced inhibition, we measured the effects ofthe uncharged
local anesthetic benzocaine on Ca-ATPase activity and found
no inhibition by benzocaine between 0 and 1 mM (not
shown). To determine whether the regulatory state of PLB
affected lidocaine-induced inhibition of the Ca-ATPase, we
added PLB Ab to CSR at ISO nM [Ca) (to remove the in-
hibitory effects of PLB). Addition of PLB Ab did not change
the extent of inhibition of the Ca-ATPase by lidocaine (not
shown), suggesting that PLB does not influence lidocaine-
induced inhibition of the Ca-ATPase.
Effects of lidocaine on the rotational dynamics of
the Ca-ATPase
When lidocaine is added to ERITC-CSR at 100 JLM [Cal, it
decreases the apparent rate of TPA decay and increases the
residual anisotropy (Fig. 4). A slower anisotropy decay may
be due to either (1) decreased rotational diffusion of
Ca-ATPase oligomers due to decreased lipid fluidity (T/"f/;
Eq. 11), or (2) formation of larger Ca-ATPase oligomers
5 10 15 20 25 30
LIDOCAINE (mM)
~2.0
[lidocaine]
0
::i ~ •8mM~~ 1.5 )~ 16mM:> •~ 32mM ....()
« 1.0
....
Q) yUl<U~ 0.5
<J=
<U()
0.00 2 3 4 5
FREE Ca2+ ( JiM)
FIGURE 2 Ca-ATPase activity at 25°C between 0 and 5 p.M [Cal in the
presence of 0 <-), 8 (e), 16 (.), and 32 (.&.) mM lidocaine, as described
in Materials and Methods (IV, p.mol of ATP hydrolyzed/mg SR protein!
min). Each point represents the average of four experiments.
~ 1.a.---'t~II:>
~
~
5l 0.8
<U
0..
~
~ 0.6
w
>~
w 0.4 t:........'---'~---'-~--'-~-'-~-'---~L.....J
0::: 0
FIGURE 3 Relative Ca-dependent ATPase activity at 25°C (normalized
to the Ca-ATPase activity in the absence of lidocaine at each Ca concen-
tration) at 150 nM <-), Ip.M (e), 20 p.M (.), 100 p.M (.&.), and 500 p.M
(T) [Cal and at 20 p.M [Ca] + 0.5 M LiCI (X) in the absence and presence
of lidocaine, as described in Materials and Methods. Each point represents
the average of three experiments :!: SE.
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FIGURE 4 TPA decays of ERITC-CSR at 25°C and 100 ILM [Ca] in
presence of 0, 1, 5, and 10 mM lidocaine.
0.000 200 400 600 800
TIME (~sec)
(increase in a; Eq. 11). It was previously determined that
changes in Ca-ATPase oligomeric state and not SR lipid
fluidity were responsible for lidocaine-induced increases
in the residual anisotropy of ERITC-skeletal SR (Kutchai
et aI., 1994). Therefore, we conclude that the increase in
residual anisotropy induced by lidocaine in ERITC-CSR
is due to an increased fraction of immobile Ca-ATPase
aggregates (1;; Eq. 6).
Because lidocaine-induced inhibition of Ca-ATPase ac-
tivity was dependent upon the concentration of Ca (or LiCI)
present, we determined the effects of Ca and 0.5 M LiCI on
lidocaine-induced aggregation of the Ca-ATPase. TPA de-
cays of ERITC-CSR in the absence and presence of 5 mM
lidocaine at 50 nM, 150 nM, 100 Il-M, and 500 Il-M [Cal are
shown in Fig. 5. At 50 and 150 nM [Cal (Fig. 5A), 5 mM
lidocaine slowed the rate of TPA decay but did not have an
effect on the residual anisotropy. At 500 Il-M [Cal, 5 mM
lidocaine increased the residual anisotropy of ERITC-CSR
but not to the extent observed at 100 Il-M [Cal (Fig. 58).
Addition of 0.5 M LiCI to ERITC-CSR at 100 Il-M [Cal did
Effects of halothane on the rotational dynamics
of the Ca-ATPase
We used TPA to determine the effects of halothane on the
Ca-ATPase oligomeric state in CSR. Fig. 7 shows the anisot-
not prevent aggregation (as indicated by an increase in the
residual anisotropy) of the Ca-ATPase by 5 mM lidocaine
(not shown).
Effects of halothane on Ca-ATPase activity
We determined the effects of halothane on Ca-ATPase ac-
tivity at 100 Il-M [Cal, and at 150 nM [Cal in the absence and
presence of PLB Ab, as well as after PLB phosphorylation
(Fig. 6). At 100 Il-M [Cal, halothane inhibited the Ca-ATPase
monotonically. Clinical levels of halothane have been re-
ported to be between 0.25 and 0.4 mM (Rusy and Komai,
1987; Franks and Lieb, 1994); thus, clinical levels of halo-
thane had little effect on the Ca-ATPase at very high levels
of Ca (Fig. 6). At subsaturating levels of Ca (150 nM), near
clinical levels of halothane activated the Ca-ATPase in CSR.
However, when PLB was specifically phosphorylated, or
when PLB Ab was added to mimic PLB phosphorylation,
these levels of halothane inhibited the Ca-ATPase (Fig. 6).
It has been reported previously that halothane inhibition of
the Ca-ATPase in CSR is competitive with respect to Ca
(Malinconico and McCarl, 1982). We found that at higher
levels of halothane (2-5 mM), inhibition by halothane was
more severe at low rather than high Ca concentration indi-
cating a protective effect of Ca on halothane inhibition of the
Ca-ATPase (Fig. 6). It has also been reported that inhibition
of the Ca-ATPase in CSR is dependent on the concentration
of ATP present (Blanck and Thompson, 1981). However, at
100 Il-M [Cal, ATP concentrations between 20 Il-M and 5 mM
had no effect on the relative inhibition of the Ca-ATPase by
~5 mM halothane (not shown).
lidocaine (mM)
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>-C-0 0.06
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«
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FIGURE 5 TPA decays of ERITC-CSR at 25°C. From boUom to top:
150 oM [Ca], 150 nM [Cal + 5 mM lidocaine, 50 nM [Ca], and 50 nM
[Ca]+ 5 mM lidocaine (A) and 100 ILM and 500 ILM [Ca] controls, 500 ILM
[Ca] + 5 mM lidocaine, and 100 ILM [Cal + 5 mM lidocaine (B).
A
0.10 0:--------------,
--100!1MCa
-+-150 nM Ca
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FIGURE 6 Relative Ca-dependent ATPase activity (normalized to the
Ca-ATPase activity in the absence of halothane at each Ca concentration)
at 25°C and 150 nM [Cal (e) or 100 ILM [Ca] (11), in the absence and
presence of halothane. ATPase activity at 150 nM [Ca] after PLB had been
specifically phosphorylated (.) or in the presence of PLB Ab (A.) is also
shown. PLB Ab had no effect on ATPase activity at 100 ILM [Cal in the
absence or presence of halothane (not shown). ATPase activity (ILmol of
ATP hydrolyzed/mg SR protein/min) in the absence of halothane was
0.30:!:: .01 (150 nM [Ca]), 0.72 :!:: .04 (150 nM [Ca] + Ab), 0.67 :!:: .02
(150 nM [Cal, PLB phosphorylated), and 1.23 :!:: .04 (100 ILM [Ca]).
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B
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FIGURE 7 TPA decays of ERITC-CSR at 25°C and 50 nM [Cal after
PLB had been specifically phosphorylated, in the absence and presence of
halothane.
ropy decays of ERITC-CSR at 50 nM [Cal, after PLB had
been specifically phosphorylated, in the presence of0, 1, and
3 mM halothane. Because halothane increases the fluidity of
(rabbit skeletal) SR lipid (Karon and Thomas, 1993), and the
lipid composition and fluidity are very similar in rabbit skel-
etal SR and dog CSR (Birmachu et aI., 1993), changes in SR
lipid fluidity cannot account for halothane-induced increases
in residual anisotropy. Thus, we conclude that halothane in-
creased the fraction of immobile Ca-ATPase aggregates.
We fit the anisotropy decays of ERITC-CSR in the ab-
sence and presence ofhalothane according to two models: (1)
a multiexponential decay, in which the mole fraction of im-
mobile aggregates U; = A",,'/1 - Aoo() is calculated by mea-
suring an increase in the residual anisotropy above the value
measured for SR in the absence of large aggregates (A",,' >
~, Eq. 4); and (2) the uniaxial decay model (Eq. 5), in
which the mole fraction of immobile aggregates Ui) is de-
termined directly from parameters of the fit. The mole frac-
tion of immobile aggregates (J;) determined by the two mod-
els shows excellent agreement (Table 1), suggesting that the
simple multiexponential fit can be used to obtain information
about the mole fraction of immobile Ca-ATPase species in
SR. Both models demonstrate that halothane-induced aggre-
gation correlates well with halothane-induced inhibition of
the Ca-ATPase (Table 1). Low levels of halothane (1 mM)
produced significant effects on the fraction of immobile
Ca-ATPase aggregates (J;) only in the low Ca, PLB-
phosphorylated sample. These same conditions produced
the greatest extent of Ca-ATPase inhibition at low levels of
halothane (Table 1).
The effects of halothane on the angles (Eqs. 3 and 8) be-
tween the membrane normal and emission (8.) and absorp-
tion (8.) dipoles, and the submicrosecond motion of the probe
on the protein (K; Eqs. 5, 7, and 8) are plotted in Fig. 8 A.
Halothane appears to increase the extent of fast probe mo-
tion, without changing the angles between the absorption and
emission dipoles and the membrane normal. The effects of
%
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FIGURE 8 (A) The values of the probe dipole angles (relative to the
membrane normal) 8., 8., and II (see Materials and Methods), and the fast
motion factor K, determined by fitting to the uniaxial model (see Materials
and Methods) TPA decays of ERITC-CSR at 25°C and 50 nM [Cal (0), 50
nM [Ca] with PLB phosphorylated (7), and 100 j..LM [Ca] <-), in the absence
and presence of halothane. (B) The values of13 (mole fraction of slowly
rotating Ca-ATPase oligomers) and h. (mole fraction of immobile
Ca-ATPase oligomers; see Table 1) determined by fitting TPA decays under
the conditions described above.
-11- 100 f!M Ca
--0-50 nM Ca
----<1- 50 nM Ca, PLB phosphorylated
100 j..LM Ca 0.27 0.29 :!: 0.D1
+ 1 mM halothane 0.27 0.30:!: 0.02 8:!:3
+ 3 mM halothane 0.28 0.35 :!: 0.01 18 :!: 2
Low Ca 0.50 0.48:!: 0.01
+ 1 mM halothane 0.47 0.48 :!: 0.D1 Stimulated
+ 3 mM halothane 0.58 0.55 :!: 0.D1 43:!: 4
Low Ca, PLB phosphorylated 0.45 0.4O:!: 0.01
+ 1 mM halothane 0.47 0.46:!: 0.02 28:!: 8
+ 3 mM halothane 0.51 0.51 :!: 0.01 67:!: 5
halothane on the mole fraction of slowly rotating species (/3)
and immobile species (fJ determined by fitting the TPA de-
cays according to the uniaxial model are also plotted in Fig.
8E. Halothane increased the values ofJ; and decreased the
values off; (aggregated the Ca-ATPase) under all conditions
measured except at low Ca and low (1 mM) halothane, in
which f3 increased and J; decreased (indicating dissociation
of Ca-ATPase aggregates). Halothane-induced activation of
the enzyme was seen only under these same conditions (Fig.
The fraction of immobile Ca-ATPase aggregates (J;) determined by fitting
TPA decays of ERITC-CSR at 25°C in the presence of 0-3 mM halothane
to the uniaxial and muItiexponential (J; = ~'/1-~) models (see Mate-
rials and Methods) compared with the percent inhibition of the Ca-ATPase
(data from Fig. 6). To facilitate fitting to the more complex uniaxial model,
TPA decays from three experiments were averaged, and the averaged TPA
decay was fit (see Karon and Thomas, 1993). For the multiexponential
model, three individual TPA decays were fit, and the values in the table
represent the average of three experiments :!: SE. Low Ca levels are 50 nM
(for TPA decays) and 150 nM (for activity experiments).
TABLE 1 TPA Parameters of ERITC-cSR and enzymatic
activity at 0-3 mM halothane
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5). Thus, the uniaxial model not only shows that halothane-
induced aggregation of the Ca-ATPase correlates well with
inhibition (Table 1) but also that halothane-induced activa-
tion of the Ca-ATPase (at low halothane and low Ca) cor-
relates with dissociation into smaller oligomers. In skeletal
SR, agents that aggregate the Ca-ATPase inhibit enzyme
function, whereas agents that dissociate Ca-ATPase oli-
gomers activate the enzyme (Mahaney and Thomas, 1991;
Voss et aI., 1991; Bigelow and Thomas, 1987; Birmachu and
Thomas, 1990). For the case of halothane in CSR, this same
relationship between Ca-ATPase oligomeric state and en-
zymatic function is seen, but halothane can either aggregate
and inhibit (under most circumstances) or dissociate and ac-
tivate (only at low Ca and low halothane concentrations) the
enzyme.
DISCUSSION
Ca uptake versus ATPase activity in the presence
of anesthetic agents
Anesthetic agents may affect in vitro measures of Ca regu-
lation in SR by at least three independent mechanisms:
(1) inhibition or activation of the Ca-ATPase; (2) inhibition
or activation of the Ca release channel; or (3) change in the
rate of passive Ca leak from SR, which can affect both the
rate of Ca uptake and ATP hydrolysis measured (Bigelow
and Thomas, 1987; Frazer and Lynch, 1992; Karon and
Thomas, 1993; Kutchai et aI., 1994). Previous attempts to
assess anesthetic action on the Ca-ATPase in SR have found
that lidocaine inhibits Ca-ATPase function in CSR, whereas
halothane has been found to either activate or inhibit enzy-
matic activity (Lain et aI., 1968; Katz et aI., 1975; Casella
et aI., 1987; Frazer and Lynch, 1992). One study has found
that halothane induces a passive leak of Ca from SR vesicles,
which may explain conflicting results. The physiological rel-
evance of this action is undetermined, as the halothane-
induced passive leak probably does not occur in vivo (Frazer
and Lynch, 1992). Furthermore, both halothane and lido-
caine have been found to increase Ca-ATPase activity by
inducing passive Ca leak in light skeletal SR, which lacks a
substantial population of Ca release channels (Karon and
Thomas, 1993; Kutchai et aI., 1994). Moreover, halothane
has been found to activate Ca release channels in both skel-
etal and cardiac SR (Frazer and Lynch, 1992; Louis et aI.,
1992).
Our study suggests that the effects of anesthetics on Ca
uptake in CSR depend largely on the physiological state of
the Ca release channel. When the channel is not inhibited,
anesthetic-induced passive leak from SR vesicles is not likely
to influence the apparent rate of Ca uptake, as the SR is
already quite leaky to Ca via the release channel. In the pres-
ence of ruthenium red, lidocaine may first increase the rate
of passive Ca leak, which results in an apparent decrease in
the rate of Ca uptake. Higher concentrations of lidocaine
decrease the rate of Ca uptake by inhibiting the Ca-ATPase
(Fig. 1). Thus, the most interpretable in vitro indicator of
anesthetic effects on Ca-ATPase function is Ca-ATPase ac-
tivity in the presence of ionophore, rather than Ca uptake
measurements. For this reason, Ca-ATPase activity in the
presence of ionophore was used to detect anesthetic-induced
changes in Ca-ATPase function in this study.
Lidocaine effects on Ca-ATPase activity and
oligomeric state
It has previously been shown that lidocaine and other local
anesthetics inhibit the Ca-ATPase in CSR and that this in-
hibition is competitive with respect to Ca (Katz et aI., 1975).
We found that lidocaine inhibited the Ca-ATPase in CSR,
and this inhibition did not change the apparent Km of the
enzyme for Ca (Fig. 2). However, concentrations of Ca
greater than necessary to saturate the high affinity Ca binding
site did protect the enzyme from lidocaine-induced inhibition
(Fig. 3). To further define this effect, we added 0.5 M LiCl
in the presence of 20 ILM [Ca] and found no inhibition of
Ca-ATPase activity by 0-30 mM lidocaine. In addition, we
added up to 1 mM (as much as is soluble in water) benzocaine
to SR to determine whether this uncharged local anesthetic
would inhibit Ca-ATPase activity. Although the concentra-
tion of benzocaine added was much less than the concen-
tration of lidocaine used, the buffer:lipid partition coefficient
of benzocaine is at least twice as great as that for lidocaine
(Strichartz et aI., 1990), so membrane concentrations of ben-
zocaine were comparable with those used for lidocaine. No
inhibitory effects ofbenzocaine were observed. We conclude
that cationic charge is essential to the inhibitory mechanism
of lidocaine. This suggests that lidocaine interacts with an-
ionic sites in the cytoplasmic domain of the Ca-ATPase to
inhibit the enzyme.
We have found that lidocaine aggregates the Ca-ATPase
in CSR (Fig. 4). In contrast to the protective effect of Ca on
lidocaine-induced inhibition, lidocaine-induced aggregation
of the Ca-ATPase showed no clear dependence on [Cal (Fig.
5). Addition of 0.5 M LiCI at 100 ILM [Cal did not abolish
the Ca-ATPase aggregation induced by 0-5 mM lidocaine.
In contrast, lidocaine-induced inhibition (from 0 to 30 mM
lidocaine) was prevented by addition of 0.5 M LiCI at 20 ILM
[Cal (Fig. 3). It is believed that the charged and uncharged
lidocaine species play separate roles in inhibition ofNa chan-
nels (Bokesch et aI., 1986; Wendt et aI., 1993). Similarly,
lidocaine-induced aggregation of the Ca-ATPase could in-
volve separate interactions of the hydrophobic and hydro-
philic domains of lidocaine or of the uncharged (hydropho-
bic) and charged (hydrophilic) species. Nevertheless, it is
clear that lidocaine-induced inhibition is dominated by cat-
ionic interaction with a hydrophilic (cytoplasmic) domain of
the Ca-ATPase.
Comparison of lidocaine effects in skeletal and
cardiac SR
Lidocaine has previously been shown to inhibit and aggre-
gate the Ca-ATPase in skeletal SR (Kutchai et aI., 1994). In
skeletal SR at 20 ILM [Cal, approximately 75 mM lidocaine
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is needed to inhibit Ca-ATPase activity by one half (Kutchai
et aI., 1994). In CSR at 20 I-tM [Cal, approximately 30 mM
lidocaine is needed to inhibit Ca-ATPase activity by one half
(Fig. 3). The concentration of lidocaine necessary to produce
detectable changes in the residual anisotropy of ERITC-
skeletal SR at 100 I-tM [Cal is 8.5 mM (Kutchai et aI., 1994).
The residual anisotropy of ERITC-CSR at 100 I-tM [Cal is
increased by lidocaine concentrations as low as 1 mM (Fig.
4). Thus, lidocaine inhibits and aggregates the Ca-ATPase in
CSR at lower concentrations than required in skeletal SR.
This could be due to (1) the presence of PLB in CSR; (2) a
differential effect of lidocaine on SR lipids in cardiac as
opposed to skeletal SR; or (3) a differential affinity for li-
docaine between the cardiac and skeletal isoforms of the
enzyme. The lipid environments of skeletal and cardiac SR
are nearly identical (Birmachu et aI., 1993), and we have
determined that PLB Ab did not change the extent of
Ca-ATPase inhibition by lidocaine. Thus, our results suggest
that the cardiac isoform of the Ca-ATPase has a higher af-
finity for lidocaine than the skeletal isoform.
It has recently been shown that polyamines, such as sper-
mine and spermidine, inhibit the Ca-ATPase in skeletal SR
at millimolar concentrations (Hughes et aI., 1994). These
authors concluded that polyamines bound predominantly to
an anionic site on the cytoplasmic domain of the skeletal
isoform and that this may represent a site of PLB interaction
with the cardiac isoform of the Ca-ATPase (Hughes et aI.,
1994). Our finding that lidocaine inhibition and aggregation
occur with higher affinity in cardiac rather than skeletal SR
suggest that a cytoplasmic domain on the cardiac isoform of
the enzyme is more sensitive to the action of cationic com-
pounds. Local anesthetics similar to lidocaine have been
shown to interact with SR near the headgroup of the lipids
or at the lipid-protein interface (Anteneodo et aI., 1994;
Louro et aI., 1994). Thus, lidocaine may interact with anionic
residues in the stalk domain of the Ca-ATPase, which are
predicted to be near the membrane surface (Brandl et aI.,
1986). However, the action of lidocaine was not dependent
on the regulatory state of PLB (presence of Ab). Thus, we
cannot conclude that an anionic site in the stalk domain of
the Ca-ATPase is the site of interaction for both PLB and
lidocaine. Rather, the anionic residues in the stalk domain
may interact with lidocaine and facilitate PLB-induced in-
hibition and aggregation of the Ca-ATPase.
Effects of halothane on Ca-ATPase activity and
oligomeric state
We have found that halothane inhibits the Ca-ATPase in CSR
and that both high Ca concentration and PLB interaction with
the Ca-ATPase (which occurs at low Ca concentration in the
absence of PLB phosphorylation or PLB Ab) protect against
this inhibition (Fig. 6). This is in agreement with a previous
study that found that halothane inhibition of the Ca-ATPase
in CSR was competitive with respect to Ca (Malinconico and
McCarl, 1982).
The nonionic detergent C12Es also activates the
Ca-ATPase in CSR only at low [Cal. At high [Calor when
PLB is phosphorylated, C12Es inhibits the Ca-ATPase (Lu
and Kirchberger, 1994). These authors concluded that C12Es
may physically dissociate PLB from the Ca-ATPase, result-
ing in enzymatic activation at low Ca (Lu and Kirchberger,
1994). It is possible that low levels of halothane might also
dissociate PLB from the Ca-ATPase, activating the enzyme;
whereas higher levels of halothane might act directly on the
Ca-ATPase to inhibit enzymatic activity. More investigation
is needed to define the mechanism of PLB and Ca protection
against halothane-induced inhibition of the Ca-ATPase. It
has also been reported that halothane inhibition of Ca uptake
in CSR is dependent upon the concentration of ATP present
(Blanck and Thompson, 1981). We found no effect of [ATPl
on halothane-induced inhibition of Ca-ATPase activity. Be-
cause ATP has also been shown to activate the Ca release
channel in skeletal SR (Mickelson et aI., 1989), it is possible
that Ca release rates were modified by ATP, resulting in
changes in the rate of Ca uptake measured.
Halothane aggregates the Ca-ATPase in CSR (Fig. 7), and
this aggregation correlates well with halothane-induced in-
hibition of the enzyme (Table 1). This suggests that
halothane-induced aggregation of the Ca-ATPase plays a
role in the mechanism of halothane-induced inhibition. We
have fit the TPA decays of ERITC-CSR according to two
models and found that the fraction of immobile aggregates
calculated (1;; Eq. 6) by the simple multiexponential model
(Eqs. 2-4 and 6) agrees well with the fraction of immobile
aggregates determined by fitting the decays to the analytical
function that describes uniaxial diffusion ofa membrane pro-
tein (Eqs. 5 and 7-10 and Table 1). Halothane increased the
rapid submicrosecond motion of the ERITC probe but did not
affect the angles between the membrane normal and the
probe's absorption and emission dipoles (Fig. 8A). Because
halothane does not change these probe angles, the value of
Aoo() will remain constant with halothane addition (Eqs. 3 and
4), so that halothane-induced increases in A",,' must be due to
an increased mole fraction of immobile Ca-ATPase aggre-
gates. As was demonstrated for TPA decays of ERITC-
skeletal SR (Cornea and Thomas, 1994; Mersol et aI., 1995),
the simple multiexponential model can be used to fit TPA
decays and determine the mole fraction of immobile
Ca-ATPase aggregates in CSR.
Comparison of halothane effects in skeletal and
cardiac SR
We have previously observed that halothane activates and
dissociates Ca-ATPase oligomers in skeletal SR (Karon
and Thomas, 1993). In CSR, halothane inhibits and aggre-
gates the Ca-ATPase. Halothane inhibition and aggregation
are Ca-dependent in CSR, whereas we did not observe Ca
dependence of halothane action in skeletal SR (data not
shown). The opposite effects of halothane in skeletal SR
and CSR could be due to the presence of PLB in CSR, as
halothane effects in CSR are dependent upon the regulatory
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state of PLB. However, phosphorylation of PLB (or PLB Ab)
accentuated differences between skeletal SR and CSR (i.e.,
inhibition and aggregation were greater). Therefore, differ-
ential effects of halothane between skeletal SR and CSR must
be due to either (1) PLB effects that occur exclusively under
conditions (high [Ca] or PLB phosphorylation) that do not
allow PLB regulation of the Ca-ATPase, or (2) halothane
must interact with the cardiac isoform of the Ca-ATPase in
a manner distinct from the skeletal isoform. More investi-
gation is needed to determine the roles ofPLB and the cardiac
isoform of the Ca-ATPase in anesthetic perturbation of SR
function.
General anesthetics (e.g., halothane) are known to depress
myocardial contractility at clinical levels, and this may be
due to a perturbation of SR Ca regulation (Rusy and Komai,
1987). Halothane activates Ca release in both skeletal SR and
CSR (Frazer and Lynch, 1992; Louis et aI., 1992), but halo-
thane alters intracellular Ca levels only in cardiac muscle
(Rusy and Komai, 1987; Iaizzo et aI., 1988). A differential
effect of halothane between skeletal SR and CSR could help
explain anesthetic depression of myocardial contractility via
SR Ca regulation. We find that halothane has opposite effects
on the Ca-ATPase in skeletal SR and CSR. Halothane is also
known to sensitize the heart towards arrhythmias induced by
administration of l3-adrenergics (Price and Ohnishi, 1980).
As PLB is the predominant protein phosphorylated in SR
after l3-adrenergic stimulation (Lindermann et aI., 1983),
and phosphorylation of PLB sensitizes the Ca-ATPase to
inhibition by halothane, a sudden reduction in the rate of
Ca uptake may occur after l3-adrenergic stimulation in the
presence of halothane.
CONCLUSIONS
Lidocaine, a cationic local anesthetic, and halothane, a hydro-
phobic general anesthetic, have different functional effects in
cardiac SR, and these anesthetic effects are different from those
in skeletal SR. Both of these differences can be explained to a
remarkable extent by a single physical model: Aggregation in-
hibits the Ca-ATPase. Lidocaine inhibits and aggregates the Ca-
ATPase in cardiac SR, with both effects occuring at lower levels
than in skeletal SR. Lidocaine's effects are primarily due to elec-
trostatic interactions with an anionic site on the cytoplasmic do-
main of the Ca-ATPase, and this site may facilitate PLB-induced
Ca-ATPase aggregation. Halothane inhibits and aggregates the
Ca-ATPase in cardiac SR under most conditions, opposite its
effects in skeletal SR. PLB phosphorylation, which is thought to
uncouple PLB from the Ca-ATPase, increases the inhibitory ef-
feet ofhalothane, indicating that the opposite effects ofhalothane
in cardiac and skeletal SR are not easily explained by the pres-
ence of PLB in cardiac SR. The mechanism of halothane-
induced inhibition of the Ca-ATPase in cardiac SR involves for-
mation of large Ca-ATPase oligomers.
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